Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer

Autor: Levent Elmas, Vildan Caner, G. Ozan Çetin, Gulseren Bagci, Nur Büyükpınarbaşılı, Emre Tepeli, Füsun Düzcan
Rok vydání: 2011
Předmět:
Male
excision repair cross complementing group 1 gene
genetic association
Non-small cell lung cancer
molecular pathology
oncogene
Carcinoma
Non-Small-Cell Lung
messenger RNA
lung non small cell cancer
article
gene expression regulation
General Medicine
Middle Aged
Immunohistochemistry
DNA-Binding Proteins
Gene Expression Regulation
Neoplastic
aged
female
Real-time polymerase chain reaction
real time polymerase chain reaction
immunohistochemistry
histopathology
Biomarker (medicine)
Female
genetic marker
down regulation
Nucleic Acid Amplification Techniques
medicine.drug
Genetic Markers
DNA
Complementary
DNA repair
Biology
Real-Time Polymerase Chain Reaction
Real-time quantitative PCR
male
Genetics
medicine
Humans
controlled study
human
RNA
Messenger
Lung cancer
protein expression
Molecular Biology
gene identification
Aged
Cisplatin
excision repair cross complementing protein 1
cancer staging
Cancer
DNA
Endonucleases
medicine.disease
major clinical study
Molecular biology
human tissue
clinical feature
gene function
validation process
Cancer research
ERCC1
upregulation
IHC
Nucleotide excision repair
Zdroj: Molecular Biology Reports. 39:335-341
ISSN: 1573-4978
0301-4851
DOI: 10.1007/s11033-011-0743-0
Popis: Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critical role in nucleotide excision repair pathway and having a significant influence on genomic instability. Some studies support that ERCC1 might be a potential predictive and prognostic marker in non-small cell lung cancer (NSCLC). ERCC1 has also been shown to be a promising biomarker in NSCLC treated with a cisplatin-based regimen. Therefore, the determination of ERCC1 expression at DNA, mRNA and protein level in different stages of NSCLC is still an important topic in the cancer. Ninety-one formalin-fixed paraffin-embedded tumor samples histopathologically diagnosed as NSCLC were examined in this study. ERCC1 expression at protein level were scored by immunohistochemistry. The gene amplification and mRNA expression levels for ERCC1 were determined by real-time quantitative PCR. There was complete concordance among the three methods in 39 tumor samples (42.9%). A strong correlation was found between DNA amplification and mRNA expression (r = 0.662) while there was no correlation between mRNA and protein assessment for ERCC1 expression (r = -0.013). ERCC1 expression at mRNA and DNA level (63.1 and 84.2%, respectively) in tumors at stage III was higher than at the other stages. In contrast, the protein expression at stage II and III (56.6 and 52.6%, respectively) of NSCLC was lower than that of tumors with stage I NSCLC. These results show that the mechanism by which ERCC1 expression might play a role in tumor behavior. This study was also confirmed that the appropriate validation and qualification in methods used for ERCC1 status were needed before its clinical application and implementation. © 2011 Springer Science+Business Media B.V.
Databáze: OpenAIRE
Externí odkaz: